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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron neurodegenerative disease. 
Although it has been classically considered as a motor system circumscribed disease, there is an 
increasing amount of evidence highlighting the involvement of other neural and non-neuronal 
systems. In this review, we will discuss currently existing literature regarding the involvement of the 
sensory system in ALS. Human studies have reported intradermic small fibre loss, sensory axonal 
predominant neuropathy, as well as somatosensory cortex hyperexcitability. In line with this, ALS 
animal studies have demonstrated the involvement of several sensory components. Specifically, they 
have highlighted the impairment of sensory-motor networks as a potential mechanism for the 
disease. The elucidation of these “non-motor” systems involvement, which might also be part of the 
degeneration process, should prompt the scientific community to consider ALS as a pure motor 
neuron disease, which may in turn result in more holistic research approaches. 
 
ABBREVIATIONS 
ALS: amyotrophic lateral sclerosis 
BMP: bone morphogenic protein 
DRG: dorsal root ganglia 
DTI: diffusor tensor imaging 
fALS: familial amyotrophic lateral sclerosis 
FTLD: frontotemporal lobal degeneration 
GAP-43: growth-associated protein 43 
LEPs: laser evoked potentials 
MEP: motor evoked potential 
MN: motor neuron 
MRI: magnetic resonance imaging 
MT: magnetization transfer 
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PMN: progressive motor neuronopathy  
rsfMRI: resting state functional MRI 
sALS: sporadic amyotrophic lateral sclerosis 
SEPs: sensory evoked potentials 
SGCs: satellite glial cells 
TBCE: tubulin binding cofactor E 
TMS: transcranial magnetic stimulation  
 
1. INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disease involving motor 
neurons (MNs) (Riancho et al. 2019). The incidence of ALS ranges between 0.7 and 3 cases per 
100,000 habitants, and is more frequent among Caucasians (Chio et al. 2013; Riancho et al. 2016). 
ALS is characterised by progressive muscular atrophy and weakness, which commonly leads to death 
within 2-3 years after diagnosis which is usually related to respiratory failure (van Es et al. 2017). 
Histologically, ALS shows MN loss accompanied by atrophy at both the motor cortex and spinal cord 
anterior horn as well as corticospinal tract sclerosis (Zufiria et al. 2016). With the exception of cases 
related to SOD1 and FUS, typically, ALS MNs exhibit TDP43 intracytoplasmic aggregates, which have 
been considered the hallmarks of ALS (Riancho et al. 2019).  
ALS cases can be divided into familial ALS (fALS) and sporadic ALS (sALS) (Zufiria et al. 2016). fALS 
cases, which represent 5-10% of total cases, are related to mutations in specific causative genes 
(C9ORF72, SOD1, TARDBP, FUS etc.) which directly induce MN degeneration (Al Chalabi and 
Hardiman 2013). sALS cases are considered to be secondary to the interaction between the 
individual genetic risk and environmental conditions. Upon this conception, ALS would develop in 
individuals in whom the sum of genetic risk, ageing, and environmental exposure would reach a 
particular threshold, upon which, specific disease mechanisms would be triggered and subsequently 
auto perpetuated (Riancho et al. 2018). 
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Although fALS represents a small percentage of cases, its study is of great importance because it can 
help shed light on the pathogenesis of the disease, not only in the familial cases, but also in the 
sporadic ones. Although the pathogenesis of ALS has not been fully elucidated yet, our knowledge 
about disease mechanisms has significantly improved during last decade. In this context, several 
crucial cellular pathways, such as gene processing disorders, energetic metabolism, proteostasis, 
axonal transport, hyperexcitability, or surrounding glial cell disorders have been associated to 
degeneration of MNs (Riancho et al. 2019). Regarding hyperexcitability, it was the rationale for the 
use of riluzole, an anti-glutamate agent approved for the treatment of ALS patients with a modest 
effect in survival. 
In recent years, our paradigm of the disease has also changed, and ALS is now increasingly being 
considered as a multisystem disease rather than a MN-circumscribed disorder.  
From its initial description by Professor Charcot in the 19th century, ALS had been classically 
considered as a neurodegenerative disease exclusively affecting MNs (van Es et al. 2017). However, 
during the past few decades, an increasing number of investigations have been published supporting 
the theory that ALS might not only be a “motor system disease”. In this sense, a non-motor 
constellation of manifestations, including dysautonomic, Parkinsonian, cognitive and sensory 
problems have been reported in ALS patients (Shimizu et al. 2000; Geser et al. 2009; Ringholz et al. 
2005; van del Graaff et al 2009; McCombe et al. 2017). Probably, the most solid evidence for this 
multisystem involvement came from the identification of the C9orf72 hexanucleotide expansion as a 
shared pathogenic condition for frontotemporal lobar degeneration (FTLD) and ALS. Currently, we all 
admit that FTLD and ALS are not two independent disorders but two conditions of the same disease 
spectrum, which in up to 15% of cases may concur in the same patient (Ringholz et al. 2005). 
Furthermore, in ALS patients not meeting FTLD criteria, some degree of cognitive impairment has 
been reported. In different clinical series, cognitive impairment seems to be present in up to 50% of 
cases and has been characterised as an unfavourable independent prognostic factor (Chio et al. 
2019; Phukan et al. 2007). Cognitive disorders and their relationship with ALS have been extensively 
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studied and reviewed. However, we also consider the sensory manifestations of ALS of great 
importance (previously reviewed by Tao et al. 2018), because of two reasons. First, awareness of 
sensory disturbances might help clinicians better manage patient symptomatology in a holistic 
manner. Second, a better understanding of non-motor symptoms will potentially provide new 
perspectives for new diagnostic/therapeutic strategies.  
In this article, we will review the existing literature, both from clinical and preclinical perspectives, 
supporting the involvement of the sensory system in ALS patients and trying to incorporate it into 
the pathogenesis of the disease. For drug/molecular target nomenclature, BJP’s Concise Guide to 
Pharmacology has been followed (Alexander et al. 2015). 
 
2. CLINICAL EVIDENCES SUPPORTING THE COEXISTENCE OF SENSORY DISORDERS IN ALS PATIENTS 
2.1. Pain and sensory symptomatology in ALS patients. 
Most clinicians agree that a large proportion of ALS patients have pain or minor sensory 
symptomatology during the disease (Chio et al. 2016; Hammad et al. 2007). This has been reported 
to be particularly frequent in fALS cases secondary to SOD1 mutations (Abe et al. 1996). The first 
reports in the literature suggesting some degree of sensory alteration in patients suffering from ALS 
come from the 1960s, when Fincham et al assessed sensory nerve conduction in patients with MN 
disease (Fincham and Vanallen 1964). 
Globally, up to 20-30% of ALS patients may refer to the occurrence of sensory symptoms, although 
sensory examination is usually normal in most patients (Hammad et al 2007). Among sensory 
symptoms, tingling paraesthesia is the most frequently complaint. Occasionally, objective sensory 
loss may occur as a part of a motor neuron “plus” syndrome (including paraneoplastic and other 
complex syndromes) and might precede or follow motor symptoms. 
Pain was a mainly neglected symptom in ALS until about 15 years ago (Chio et al 2016). However, 
the importance of identification and assessment of pain in patients with ALS cannot be overlooked 
due to the fact that it has profound detrimental effects on the quality of life of ALS patients (Wallace 
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et al. 2014). Indeed, pain management is considered in the main guidelines of ALS treatment (Miller 
el al. 2009). The epidemiology of pain in the ALS spectrum has not been fully elucidated yet. There 
are few systematic studies on pain in patients with ALS and a few longitudinal studies have reported 
the frequency of pain to be between 15-85% (Chio et al 2016). Regarding pain characteristics, there 
is also a great variability in both clinical manifestations and localisation depending on whether the 
pain represents primary mechanisms or results from the secondary effects of MN degeneration. 
Primary causes of pain in ALS include pain with neuropathic features, spasticity, and cramps. Among 
them, cramps are the major cause of pain in a substantial proportion of patients, particularly in 
those with spinal onset (Caress et al 2016), while spasticity is typically observed at advanced stages. 
Secondary causes of ALS develop as the disease progresses and progressive paresis induces 
immobility, degenerative changes in connective tissue, bones, and joints, leading to musculoskeletal 
pain. In this regard, joint contractures, periscapular arthritis, and decubitus ulcers are causes of pain, 
particularly towards the end of the disease (Chio et al. 2016). Non-invasive ventilation may be 
another cause of pain in ALS patients for two reasons. On the first reason is that some patients 
present poor adaptation to ventilatory devices, while the second possible reason is the fact that non-
invasive ventilation is commonly associated to skin lesions on the nasal bridge. In addition, dyspnoea 
itself, is known to activate several nociceptive pathways (Bouvier et al 1985). Treatment strategies 
for pain in ALS should be directed to reduce its intensity and, if possible, prevent it from becoming 
chronic. Pharmacological treatments, sometimes combined with physiotherapy, constitute the main 
approach for primary types of pain, whereas non-pharmacological strategies are generally indicated 
for the secondary sources of pain. (Chio et al. 2016) 
 
2.2. Involvement of sensory components in ALS patients 
According to the different components of the sensory pathway, we have divided existing reports into 
three distinct categories: i) sensory peripheral nervous system ii) sensory ascending spinal tracts and 
iii) somatosensory cortex. Most relevant studies are summarised in Table 1. 
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2.2.1. Sensory peripheral nervous system  
The peripheral sensory pathway is made up of different components, including posterior spinal 
roots, plexus, peripheral nerves, and sensory peripheral receptors.  
Two main types of studies have focused on this level of the sensory system. First, there are a large 
number of studies assessing sensory peripheral nerve conduction, some of which included sural 
nerve biopsy. Complementarily, other researchers have investigated peripheral sensory receptors, as 
well as intraepidermal nerve fibres at the skin level. Regarding neurophysiological studies assessing 
sensory involvement in ALS patients, some important issues that might potentially bias the obtained 
results should be mentioned: first, the vast majority of reported studies included a small number of 
participants; second, as ALS is typically an adulthood disease, most of the included patients may also 
exhibit other comorbidities such as diabetes (and consequently diabetic polyneuropathy) or cervical 
myelopathy that might influence both nerve conduction studies and somatosensorial evoked 
potential, thus behaving as confounding factors; third, in a big proportion of these studies, ALS 
patients were not stratified by important parameters such as age, nutritional state or disease 
severity, conditions that could potentially influence the reported results. 
With regard to nerve conduction studies, several investigators reported some degree of sensory 
nerve conduction impairment in ALS patients. One of the earliest studies, performed by Heads et al 
(1991), provided evidence of early axonal atrophy, increased remyelination, and a predominance of 
the small diameter fibres. Importantly, these findings correlated to disease duration (Heads et al. 
1991). Not long after, and consistently with these data, another study evaluated sensory nerve 
conduction in 19 ALS patients, evidencing significant falls in potential amplitudes with preserved 
nerve conduction velocities, in comparison to healthy controls (Gregory et al. 1993). Of high interest 
is the study performed by Hammad et al (2007) which included 103 patients with a clinical diagnosis 
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of ALS. In their investigation, up to 32% and 27% of ALS patients presented with sensory symptoms 
and abnormalities in sural sensory nerve conduction studies, respectively. In addition, sural nerve 
biopsy, which was performed in 22 patients, revealed histological abnormalities in 91% of patients. 
Such abnormalities included loss of predominantly large-calibre myelinated fibres, accompanied by 
axonal loss and axonal regeneration (Hammad et al. 2007). In this line, other studies reported similar 
rates of sensory nerve conduction disorders in ALS patients, presenting ALS as a multisystem 
neurodegenerative disorder that might occasionally include some degree of sensitive neuropathy 
(Isaacs et al. 2007; Pugdahl et al. 2007). Interestingly, it has been suggested that distal sensory nerve 
conduction tests evaluating antidromic dorsal sural nerve and orthodromic medial plantar, appear 
abnormal more often than conventional sensory nerve conduction evaluations (Isak et al. 2016b). 
More recently, a cohort of 150 oriental ALS patients, with a diagnosis of definite or probable ALS, 
were retrospectively assessed. Interestingly, the analysis of sensory nerve conduction studies 
revealed that they exhibited alterations in up to 15% of patients (Liu et al. 2019). 
However, published studies evaluating peripheral sensory disturbances are not fully concordant. 
Opposite results were reported by Matamala et al (2018). In their investigation, they performed a 
case-control study involving 28 sALS patients and 28 age-matched controls and evaluated sensory 
nerve action potentials (Matamala et al. 2018). Another prospective study involving 32 sALS patients 
and 32 controls who were studied for nerve conduction and sural nerve biopsy, did not find specific 
sensory abnormalities either. However, histological analysis demonstrated abnormal axonal 
swellings among all ALS patients which were negative for growth-associated protein 43 (GAP-43), 
thus suggesting an insufficiency of regeneration in small sensory nerve fibres (Isak et al. 2017). In 
line with this, another retrospective study including 17 ALS patients who had undergone a sural 
nerve biopsy reported a significant axonal loss in more than two-thirds of the patients (Luigetti et al. 
2012).  
Regarding peripheral receptors and intraepidermal nerves, due to their important role in the 
pathogenesis of ALS, Ren et al evaluated the involvement of both sensory and autonomic nervous 
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systems by investigating the presence of TDP43 deposits in skin nerve fibres in patients and control 
subjects. Regarding sensory disorders, ALS patients showed a significant reduction in intraepidermal 
nerve fibre density as well as a significant loss in Meissner´s corpuscles (Ren et al. 2018). In addition, 
in comparison with controls, a large proportion of ALS patient biopsies demonstrated TDP-43 
deposits in nerve fibres, thus emerging as a new potential biomarker (Ren et al. 2018). In our 
opinion, these intriguing results should be taken cautiously until replicated by other groups. 
Importantly, as previously discussed, ALS patients with sensory manifestations have 
characteristically been associated with SOD1 mutations which typically do not exhibit TDP-43 
aggregates (Riancho et al. 2019). However, they are concordant with the results recently published 
by our group in which we reported abnormal TDP43 aggregates in dermic-derived fibroblasts from 
sALS patients (Riancho et al. 2020). 
The loss of both intraepidermal nerve fibres and Meissner´s corpuscles had also been reported in 
another study enrolling 41 sALS patients and 41 matched controls. Intriguingly, researchers 
described that these findings were associated to a partial reduction in skin vascular vessels, and that 
those abnormalities correlated with disease progression (Nolano et al. 2017). In this line, other 
authors also reported intraepidermal fibre loss in ALS patients, but failed to correlate the severity of 
these findings with disease onset, clinical phenotype, as well as disease course and severity (Dalla et 
al. 2016). Another study including both spinal and bulbar onset ALS patients, demonstrated that 
spinal, but not bulbar onset patients, exhibited distal small fibre neuropathy consisting of abnormal 
thermal-pain thresholds as well as reduced intraepidermal nerve fibre density (Truini et al. 2015). 
In summary, although there is not full concordance among published reports, most of them agreed 
on the presence of subtle sensory symptoms and signs of axonal predominant sensory neuropathy in 
nerve conduction studies. These findings correlated with histological findings that frequently 
evidenced a predominantly large-calibre myelinated fibre loss as well as some degree of axonal 
degeneration. These histologically subtle alterations did not often manifest clinically or 
electrophysiologically. Regarding the assessment of peripheral sensory receptors and intraepidermal 
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nerve fibres at a dermic level, it seems clear that there exists a reduction of both in ALS patients, 
particularly in the spinal forms of the disease. In favour of its biological plausibility, abnormal TDP-43 
deposits have been documented in intraepidermal nerve fibres of ALS patients. 
2.2.2. Sensory ascending spinal tracts 
Within the spinal cord, sensory tracts ascend through the dorsal (light touch, vibration, 
proprioception) and anterolateral (pain and temperature) columns. Sensory evoked potentials (SEPs) 
constitute a widely used neurophysiological technique to evaluate the transmission of sensory 
impulses at dorsal spinal columns. 
The first reported study assessing SEPs in ALS was performed almost 40 years ago and included 45 
patients with the disease (Cosi et al. 1984). The authors reported a pathological slowing of 
conduction along the central sensory pathways, that in some patients was also accompanied by a 
decreased amplitude response (Cosi et al. 1984). Subsequently, other investigators have reported a 
similar rate of SEP alterations in ALS patients, ranging from 50-60% of cases (Radtke et al. 1986, 
Theys et al 1999). Interestingly SEP differences did not significantly progress over the 180 day follow-
up period, thus suggesting that although frequent at diagnosis, sensory subclinical abnormalities are 
usually not as rapidly progressive as motor manifestations (Theys et al. 1999). Apart from the 
standard SEPs, late SEPs’ components (N60, P100), which reflect on cortical pathways involved in 
cognitive-motor functions, have been reported to be significantly depressed in ALS patients (Sangari 
et al 2018).  
In recent years, laser evoked potentials (LEPs) have emerged as a complementary tool to SEPs to 
evaluate central conduction of pain stimulus. Several authors have incorporated this technique for 
sensory assessment of ALS patients. A case-control study including 24 ALS patients and 23 controls 
concluded that the former exhibited abnormal delayed latencies when compared to healthy 
subjects, also supporting the presence of degeneration of sensory subcortical structures (Simone et 
al. 2010). One study combining both SEP and LEPs in 18 ALS patients and 31 controls, obtained 
concordant findings with previous literature, suggesting an impairment of sensory tracts in more 
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than half of studied patients. Interestingly, LEPs appeared as a more sensitive tool than SEPs to 
evaluate sensory disturbances in patients with MN disease (72% and 56%, respectively) (Isak et al. 
2016a). 
Magnetic resonance imaging (MRI) has also been used to assess spinal sensory tracts in ALS patients. 
Cohen-Adad et al (2013) performed the first study in which diffusion tensor imaging (DTI) and 
magnetisation transfer (MT) were measured in the spinal cord of 29 patients and 21 healthy 
controls, respectively. Interestingly, at both lateral and dorsal segments of the spinal cord, significant 
differences between ALS patients and control subjects were detected in DTI and MT sequences, 
suggesting a subjacent degeneration of the two sensory dorsal and anterolateral tracts (Cohen-Adad 
et al. 2013). In line with these findings, a complementary investigation examined sensory spinal 
columns combining DTI sequences at dorsal columns and SEPs after median and ulnar nerve 
stimulation. Taken together, at early stages of the disease, DTI spinal imaging and SEPs were able to 
identify that up to 85% of ALS patients have subclinical sensory impairment (Iglesias et al. 2015).  
In conclusion, SEPs and LEPs appear as useful tools for evaluating ascending sensory tracts at the 
spinal cord. In comparison to healthy controls, an important proportion of ALS patients show 
prolonged nerve conduction latencies within these techniques, thus suggesting some degree of 
impairment at spinal levels. In this regard, LEPs seem to be a bit more sensitive than SEPs in 
identifying such alterations. Likewise, DTI and MT MRI sequences have demonstrated spinal 
alterations at both dorsal and anterolateral tracts, reinforcing the concept, that although 
asymptomatic in most cases, sensory ascending tracts frequently exhibit some degree of alteration 
in ALS patients.  
2.2.3. Somatosensory cortex 
The somatosensory cortex constitutes the highest level in the sensory pathway. It comprises the 
primary somatosensory cortex and the secondary somatosensory cortex. In a simplistic 
representation, the former would be responsible for processing somatic sensations, while the latter 
would be responsible for the perception of that sensation. The primary somatosensory 
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cortex is located in the parietal lobe at the postcentral gyrus. It is situated just posterior to the 
central sulcus adjacent to the primary motor cortex. Interestingly, somatosensory cortex, particularly 
its secondary areas, are widely interconnected with other brain areas, including the motor cortex 
(Brazis P et al. 2011). 
Based on their close anatomical and functional relationship, Mochizuki et al evaluated the number of 
neurons in the primary motor and somatosensory cortex in ALS patients. Interestingly, the authors 
described a significant decrease of neurons and Betz cells in both locations compared to control 
subjects. In addition, a positive correlation between the number of neurons at motor and 
somatosensory cortex was evidenced, thus suggesting that interdependent mechanisms may exist 
between these areas once neurodegeneration is initiated (Mochizuki et al. 2011). These findings are 
also supported by isolated clinical cases of ALS patients, in whom “unexplained” parietal lobe 
atrophy was evidenced by MRI with disease progression (Shimizu et al. 2020). 
Recently, the concept of brain connectome modified our conception of brain functions. Upon this 
conception, the distinct cerebral areas would be very widely interconnected, resulting in different 
functional networks (Hodge et al. 2016). In this regard, to investigate functional coherence within 
the sensory-motor network, 12 ALS patients were studied by resting state functional MRI (rsfMRI) 
analysis. After comparing ALS patients with healthy controls, a decreased functional coherence was 
evidenced at distinct sensory-motor network areas. Intriguingly, sensory-motor network impairment 
in specific areas, such as right postcentral gyrus – precentral gyrus – superior frontal gyrus, was 
associated with lower ALSFRS-r scores, suggesting a more severe disease evolution (Zhou et al. 
2014). 
Lately, somatosensory cortex hyperexcitability is also being considered as a potential biomarker for 
short survival in patients with ALS. This relies on the theory that at a particular point of the disease, 
somatosensorial cortex hyperexcitability might reflect a compensatory mechanism of sensory cortex 
for motor disturbances (Hamada et al. 2007).  
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According to this hypothesis, Shimizu et al (2018) studied a cohort of 145 sALS patients and 73 
healthy controls and followed them until death or tracheotomy. Intriguingly, median survival was 
significantly shorter in patients who had larger somatosensory cortical amplitudes in SEPs. 
Subsequent multivariate analyses identified a more pronounced N20p-P25p amplitude as an 
independent prognostic factor (Shimizu et al. 2018). In line with this study, a marked disinhibition of 
somatosensory cortex in ALS patients from the second year of disease evolution has been recently 
reported (Nardone et al. 2020). 
In addition to the sensory-motor integration at a cortical level, there are also relevant connections 
between sensory and motor systems at the spinal cord.  
The dorsal root ganglia contain the cell bodies of neurons of the sensory pathway that transmit the 
somatosensory information from the periphery to the CNS through the dorsal and anterolateral tracts 
of the spinal cord (Haberberger et al., 2019). Apart from transmitting sensory information, 
proprioceptive sensory neurons are key in modulating motor behaviours by integrating the sensory 
and motor systems into the CNS. Thus, proprioceptive DRG neurons transmit peripheral information 
about muscle contractions to lower MNs as a feedback system to generate appropriate motor 
responses (Imai and Yoshida, 2018). Consequently, in addition to inducing somatosensory disorders, 
damage to proprioceptive neurons may secondarily contribute to the pathogenesis of motor 
disturbances in ALS. Differently from MNs at the anterior horn, each sensory neuron is wrapped by the 
cell bodies and laminar processes of several satellite glial cells (SGCs), forming a morphological and 
functional unit (sensory neuron – SGC units) (Haberberger et al 2019). SGCs play an important 
regulatory role in sensory neuron function, particularly in controlling the neuronal microenvironment. 
(Haberberger et al. 2019).  
Recently, Sangari el al (2016) reported an impaired spinal integration of these systems in ALS 
patients. In their study, transcranial magnetic stimulation (TMS) was applied over the motor cortex 
to induce motor evoked potential (MEP) in contralateral triceps. Then, median and ulnar nerve 
stimulations at wrist level were combined with TMS to evaluate the resulting changes in MEPs. 
 
 
This article is protected by copyright. All rights reserved. 
Although there were no differences in MEP recruitment curves between ALS and healthy subjects, 
MEP threshold was significantly higher in the latter. In addition, although nerve stimuli MEPs 
increased in both groups, but facilitation was stronger in ALS patients. This, led the authors to 
speculate that spinal network properties likely compensate for depression of afferent inputs, thus 
leading to MN hyperexcitability which may in turn contribute to excitotoxicity (Sangari et al 2016). 
In summary, an important number of studies support the involvement of somatosensory cortex and 
sensory-motor networks in ALS patients. In this regard, different studies have pointed out to 
somatosensory hyperexcitability as an independent biomarker of short survival. 
 
3. PRECLINICAL EVIDENCE SUPPORTING THE INVOLVEMENT OF THE SENSORY SYSTEM IN ALS 
Complementary to clinical studies, several preclinical studies support some degree of sensory system 
dysfunction in this disease (Table 2). Most of them used the transgenic SOD1 mouse model. Up to 
20% of fALS cases are due to SOD1 mutations. This gene encodes the superoxide dismutase 1 
protein, which is involved in several cellular functions, including the oxidative stress response 
(Riancho et al. 2019). SOD1 mutations are also the basis of a commonly used transgenic mouse 
model expressing the human SOD1 gene with the G93A mutation (Gurney et al. 1994). High-copy 
SOD1G93A transgenic mice have been reported to recapitulate much of the pathophysiology of human 
ALS, including progressive MN degeneration, progressive neuromuscular function loss and reduced 
lifespan (Gurney et al. 1994). Despite the fact that this mouse model is based on a SOD1 familial 
form of ALS, and consequently does not exhibit the cytoplasmic TDP43 aggregates, several authors 
have highlighted its translational usefulness for the study of sALS (Bosco et al. 2010). 
Guo et al (2009) first studied sensory disturbances in the transgenic SOD1G93A murine model. In their 
study, transgenic mice were used to explore the sensory system at several levels, including dorsal 
roots, dorsal ganglia, and posterior column tracts. Interestingly, they concluded that, from an 
histological perspective, transgenic SOD1 mice exhibited significant damage in the sensory system, 
which basically consisted of Wallerian-like degeneration in axons of both dorsal root and dorsal 
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funiculus, as well as mitochondrial abnormalities in dorsal root ganglia sensory neurons (Guo et al. 
2009). Subsequently, different investigations focused on the distinct sensory pathway levels to 
assess the presence or absence of pathology. On this basis, published studies might be divided into 
those evaluating pathology at: i) dorsal root ganglion sensory neurons and large sensory conduction 
fibres, ii) small intraepidermal sensory fibres, and iii) sensory-motor networks. 
3.1. Dorsal root ganglion sensory neurons and large sensory conduction fibres 
Several reports have tried to characterise sensory disturbances in sensory neurons at the dorsal root 
ganglion and large sensory peripheral nerves. First, Vaughan et al (2015) assessed two strains of 
transgenic mice harbouring mutations in SOD1 (G93A) and TARDBP (A315T), and evaluated 
retrograde axonal transport. Interestingly, the analysis of proprioceptive nerve endings in muscle 
revealed early disturbances at Ia/II proprioceptive nerve endings in muscle spindles before the 
motor symptomatic phase had initiated. Intriguingly, in TDP43 transgenic mice, clear sensory 
abnormalities were evident even in the absence of MN axon lesions (Vaughan et al. 2015). Also, 
sensory abnormalities have been evaluated in progressive motor neuronopathy (PMN) transgenic 
mice, characterised by a missense loss of function mutation in the tubulin binding cofactor E (TBCE). 
These animals show an aggressive form of motor axon dying back and microtubule loss, similar to 
that observed in ALS patients associated to TUBA4A mutations. Histological analysis showed 
evidence of sural sensory neuropathy with axonal discontinuities and bead-like spheroids. In 
addition, transgenic mice showed a marked impairment of microtubule polymerisation in dorsal root 
ganglion neurons which would likely result in a compromised microtubule-based transport in those 
neurons, thus providing a new potential explanation for the axonal pathology in sensory nerves 
(Schafer et al. 2017). 
Coming back to the SOD1 transgenic mice model, it has been demonstrated that dorsal ganglion 
sensory neurons accumulate misfolded mutant SOD1 protein. However, this protein accumulation 
was not associated with endoplasmic reticulum stress, nor did it induce unfolded protein responses. 
If confirmed, these findings might indicate underlying differential vulnerability mechanisms between 
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anterior horn MNs and sensory neurons in ALS (Taiana et al. 2016). In the same line, Vaughan et al 
(2018) characterised mutant TDP43 A315T cultured sensory neurons and compared them with mutant 
SOD1G93A and control cultured sensory neurons, respectively. Interestingly, both SOD1 and TDP43 
mutant neurons were reported to have slower rates of neurite growth and lesser elaboration of 
neuritic branches. Mutation-bearing sensory neurons were also more sensitive to the microtubule 
inhibitor vincristine than control neurons. Interestingly, the analysis of several factors involved in 
stress responses, such as ATF3 or PERK, demonstrated important differences between SOD1 and 
TDP43 sensory neurons (Vaughan et al. 2018). 
3.2. Small intraepidermal sensory fibres 
Sensory small nerve fibres have also been studied in SOD1 transgenic mice. It has been noted that 
these mice displayed small fibre pathology with intraepidermal nerve fibre loss, reduction of 
Meissner´s corpuscles, and axonal degeneration which characteristically preceded the disease onset 
and progressed over time (Sassone et al. 2016; Rubio et al. 2016). Complementarily, the culture of 
small diameter dorsal root ganglion neurons of mutant mice showed stress features and peripherin 
56 (a peripherin splice variant) accumulation, which induced axonal damage because its dissembled 
light and medium neurofilaments subunits. These important findings suggest a new potential 
mechanism for small fibre pathology in ALS and reinforce the role of peripherin in the pathogenesis 
of the disease (Sassone et al. 2016).  
3.3. Sensory-motor networks 
Although motor manifestations are the key feature of ALS, several investigators have studied motor 
networks to elucidate whether degenerative mechanisms initiated at anterior horn MNs or in other 
cells of these motor circuits. Within this scenario, Held et al (2019) recently reported a Drosophila 
SOD1G85R knock-in model. Their results showed that transgenic larvae at early stages exhibited a 
significant motor function deterioration that was not associated with a clear degeneration of spinal 
MNs, thus suggesting that other components within the sensory-motor networks might be altered. 
Interestingly, a defect in the proprioceptor sensory neurons, which are necessary for the relay of the 
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contractile status of muscles back to the central nerve cord, was identified. Mechanistic approaches 
suggested that this defect in sensory feedback might be related to bone morphogenic protein (BMP) 
pathway (Held et al. 2019). Not long after, abnormalities in proprioceptive sensory neurons involved 
in jaw reflex were reported in SOD1 transgenic mice as another potential target for the disease. 
These included impaired action potential burst discharge related to sodium channels. Interestingly, 
other brainstem sensory neurons such as the mechanoreceptive and nociceptive trigeminal ganglion 
neurons did not exhibit pathological features (Seki et al. 2019). 
 
4. CONCLUDING REMARKS 
Although ALS has been classically considered as a motor system circumscribed disease, there is an 
increasing amount of evidence that other neurological and probably non-neurological systems may 
also be involved. This also occurs in other neurodegenerative diseases such as Parkinson´s disease in 
which non-motor symptomatology has been proved to have a great relevance in the pathogenesis of 
the disease. In this regard, the sensory system has been extensively reported both from preclinical 
and clinical studies to be affected in ALS patients. Even though they are not usually described by 
patients, due to the high heterogeneity of the disease, subtle sensory alterations seem to be present 
in a subgroup of ALS patients.  
These evidences will probably have a double positive effect. On the one hand, a better 
understanding of the clinical spectrum of the disease will translate into better care of ALS patients. 
In contrast, the identification of new, “non-motor” systems involvement, that might also be part of 
the degeneration, should prompt the scientific community to consider ALS as a non-cell-autonomous 
disease. On this basis, more holistic research approaches would hopefully translate into more 
successful results.  
 
Nomenclature of Targets and Ligands 
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Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2019/20 (Alexander et al. 2019). 
 
ACKOWLEDGEMENTS 




Abe, K., M. Aoki, M. Ikeda, M. Watanabe, S. Hirai, and Y. Itoyama. 1996. Clinical 
characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene 
mutations. J. Neurol. Sci. 136: 108-116. 
Al Chalabi, A. and O. Hardiman. 2013. The epidemiology of ALS: a conspiracy of genes, 
environment and time. Nat. Rev. Neurol. 9: 617-628. 
Alexander SPH, Cidlowski JA, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda 
E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA. 2019. 
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors. Br J Pharmacol. 176 
Suppl 1: S229-S246 
Bosco, D. A., G. Morfini, N. M. Karabacak, Y. Song, F. Gros-Louis, P. Pasinelli, H. Goolsby, B. A. 
Fontaine, N. Lemay, D. McKenna-Yasek, M. P. Frosch, J. N. Agar, J. P. Julien, S. T. Brady, and R. H. 
Brown, Jr. 2010. Wild-type and mutant SOD1 share an aberrant conformation and a common 
pathogenic pathway in ALS. Nat. Neurosci. 13: 1396-1403. 
Bouvier G, Laviolette L, Kindler F, et al. Dyspnea-pain counterirritation induced by inspiratory 
threshold loading: a laser-evoked potentials study 1985. J Appl Physiol; 112: 1166–73. 
Brazis P, Masdeu J, and Biller J. 2011. Localization in clinical neurology. 6th ed. Philadelphia: 
Lippincott Williams & Wilkins. 
Caress JB, Ciarlone SL, Sullivan EA, Griffi n LP, Cartwright MS. 2016. Natural history of muscle 
cramps in amyotrophic lateral sclerosis. Muscle Nerve; 53: 513–17. 
 
Chio, A., G. Logroscino, B. J. Traynor, J. Collins, J. C. Simeone, L. A. Goldstein, and L. A. White. 
2013. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published 
literature. Neuroepidemiology 41: 118-130. 
Chio, A., C. Moglia, A. Canosa, U. Manera, R. Vasta, M. Brunetti, M. Barberis, L. Corrado, S. 
D'Alfonso, E. Bersano, M. F. Sarnelli, V. Solara, J. P. Zucchetti, L. Peotta, B. Iazzolino, L. Mazzini, G. 
 
 
This article is protected by copyright. All rights reserved. 
Mora, and A. Calvo. 2019. Cognitive impairment across ALS clinical stages in a population-based 
cohort. Neurology 93: e984-e994. 
Chio, A., G. Mora, and G. Lauria. 2016. Pain in amyotrophic lateral sclerosis. Lancet Neurol. 
Cohen-Adad, J., M. M. El Mendili, R. Morizot-Koutlidis, S. Lehericy, V. Meininger, S. Blancho, 
S. Rossignol, H. Benali, and P. F. Pradat. 2013. Involvement of spinal sensory pathway in ALS and 
specificity of cord atrophy to lower motor neuron degeneration. Amyotroph. Lateral. Scler. 
Frontotemporal. Degener. 14: 30-38. 
Cosi, V., M. Poloni, L. Mazzini, and R. Callieco. 1984. Somatosensory evoked potentials in 
amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry 47: 857-861. 
Dalla, B. E., R. Lombardi, C. Porretta-Serapiglia, C. Ciano, C. Gellera, V. Pensato, D. Cazzato, 
and G. Lauria. 2016. Amyotrophic lateral sclerosis causes small fiber pathology. Eur. J. Neurol. 23: 
416-420. 
Fincham, R. W. and M. W. Vanallen. 1964. Sensory nerve conduction in amyotrophic lateral 
sclerosis. Neurology 14: 31-33. 
Geser, F., M. Martinez-Lage, J. Robinson, K. Uryu, M. Neumann, N. J. Brandmeir, S. X. Xie, L. 
K. Kwong, L. Elman, L. McCluskey, C. M. Clark, J. Malunda, B. L. Miller, E. A. Zimmerman, J. Qian, D. 
Van, V, M. Grossman, V. M. Lee, and J. Q. Trojanowski. 2009. Clinical and pathological continuum of 
multisystem TDP-43 proteinopathies. Arch. Neurol. 66: 180-189. 
Gregory, R., K. Mills, and M. Donaghy. 1993. Progressive sensory nerve dysfunction in 
amyotrophic lateral sclerosis: a prospective clinical and neurophysiological study. J. Neurol. 240: 
309-314. 
Guo, Y. S., D. X. Wu, H. R. Wu, S. Y. Wu, C. Yang, B. Li, H. Bu, Y. S. Zhang, and C. Y. Li. 2009. 
Sensory involvement in the SOD1-G93A mouse model of amyotrophic lateral sclerosis. Exp. Mol. 
Med. 41: 140-150. 
Gurney, M. E., H. Pu, A. Y. Chiu, M. C. Dal Canto, C. Y. Polchow, D. D. Alexander, J. Caliendo, 
A. Hentati, Y. W. Kwon, H. X. Deng, and . 1994. Motor neuron degeneration in mice that express a 
human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775. 
Haberberger RV, Barry C, Dominguez N, Matusica D. 2019. Human Dorsal Root Ganglia. Front 
Cell Neurosci; 19: 271.  
 
Hamada, M., R. Hanajima, Y. Terao, F. Sato, T. Okano, K. Yuasa, T. Furubayashi, S. Okabe, N. 
Arai, and Y. Ugawa. 2007. Median nerve somatosensory evoked potentials and their high-frequency 
oscillations in amyotrophic lateral sclerosis. Clin. Neurophysiol. 118: 877-886. 
Hammad, M., A. Silva, J. Glass, J. T. Sladky, and M. Benatar. 2007. Clinical, electrophysiologic, 
and pathologic evidence for sensory abnormalities in ALS. Neurology 69: 2236-2242. 
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson AJ, Ireland S, Gray AJG, Bruce 
L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding 
M, Davies JA, NC-IUPHAR (2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and 




This article is protected by copyright. All rights reserved. 
Heads, T., M. Pollock, A. Robertson, W. H. Sutherland, and S. Allpress. 1991. Sensory nerve 
pathology in amyotrophic lateral sclerosis. Acta Neuropathol. 82: 316-320. 
Held, A., P. Major, A. Sahin, R. A. Reenan, D. Lipscombe, and K. A. Wharton. 2019. Circuit 
Dysfunction in SOD1-ALS Model First Detected in Sensory Feedback Prior to Motor Neuron 
Degeneration Is Alleviated by BMP Signaling. J. Neurosci. 39: 2347-2364. 
Hodge, M. R., W. Horton, T. Brown, R. Herrick, T. Olsen, M. E. Hileman, M. McKay, K. A. 
Archie, E. Cler, M. P. Harms, G. C. Burgess, M. F. Glasser, J. S. Elam, S. W. Curtiss, D. M. Barch, R. 
Oostenveld, L. J. Larson-Prior, K. Ugurbil, D. C. Van Essen, and D. S. Marcus. 2016. ConnectomeDB--
Sharing human brain connectivity data. Neuroimage. 124: 1102-1107. 
Iglesias, C., S. Sangari, M. M. El Mendili, H. Benali, V. Marchand-Pauvert, and P. F. Pradat. 
2015. Electrophysiological and spinal imaging evidences for sensory dysfunction in amyotrophic 
lateral sclerosis. BMJ Open. 5: e007659. 
Imai F, Yoshida Y 2018. Molecular mechanisms underlying monosynaptic sensory-
motor circuit development in the spinal cord. Dev Dyn; 247: 581-587. 
 
Isaacs, J. D., A. F. Dean, C. E. Shaw, A. Al Chalabi, K. R. Mills, and P. N. Leigh. 2007. 
Amyotrophic lateral sclerosis with sensory neuropathy: part of a multisystem disorder? J. Neurol. 
Neurosurg. Psychiatry 78: 750-753. 
Isak, B., K. Pugdahl, P. Karlsson, H. Tankisi, N. B. Finnerup, J. Furtula, B. Johnsen, N. Sunde, J. 
Jakobsen, and A. Fuglsang-Frederiksen. 2017. Quantitative sensory testing and structural assessment 
of sensory nerve fibres in amyotrophic lateral sclerosis. J. Neurol. Sci. 373: 329-334. 
Isak, B., H. Tankisi, B. Johnsen, K. Pugdahl, N. B. Finnerup, and A. Fuglsang-Frederiksen. 
2016a. Laser and somatosensory evoked potentials in amyotrophic lateral sclerosis. Clin. 
Neurophysiol. 127: 3322-3328. 
Isak, B., H. Tankisi, B. Johnsen, K. Pugdahl, M. A. Torvin, N. B. Finnerup, P. B. Christensen, 
and A. Fuglsang-Frederiksen. 2016b. Involvement of distal sensory nerves in amyotrophic lateral 
sclerosis. Muscle Nerve 54: 1086-1092. 
Liu, J., X. Zhang, X. Ding, M. Song, and K. Sui. 2019. Analysis of clinical and 
electrophysiological characteristics of 150 patients with amyotrophic lateral sclerosis in China. 
Neurol. Sci. 40: 363-369. 
Luigetti, M., A. Conte, A. Del Grande, G. Bisogni, A. Romano, and M. Sabatelli. 2012. Sural 
nerve pathology in ALS patients: a single-centre experience. Neurol. Sci. 33: 1095-1099. 
Matamala, J. M., J. Howells, T. Dharmadasa, W. Huynh, S. B. Park, D. Burke, and M. C. 
Kiernan. 2018. Excitability of sensory axons in amyotrophic lateral sclerosis. Clin. Neurophysiol. 129: 
1472-1478. 
McCombe  PA, Wray NR and  Henderson RD. 2017. Extra-motor Abnormalities in 
Amyotrophic Lateral Sclerosis: Another Layer of Heterogeneity. Expert Rev Neurother; 17: 561-577 
 
Miller RG, Jackson CE, Kasarskis EJ, et al 2009 . Practice parameter update: the care of the 
patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and 
cognitive/ behavioral impairment (an evidence-based review): report of the Quality Standards 
Subcommittee of the American Academy of Neurology. Neurology;  73: 1227–33. 
 
 
This article is protected by copyright. All rights reserved. 
 
Mochizuki, Y., T. Mizutani, T. Shimizu, and A. Kawata. 2011. Proportional neuronal loss 
between the primary motor and sensory cortex in amyotrophic lateral sclerosis. Neurosci. Lett. 503: 
73-75. 
Nardone, R., S. Golaszewski, A. Thomschewski, L. Sebastianelli, V. Versace, F. Brigo, A. Orioli, 
L. Saltuari, Y. Holler, and E. Trinka. 2020. Disinhibition of sensory cortex in patients with amyotrophic 
lateral sclerosis. Neurosci. Lett. 722: 134860. 
Nolano, M., V. Provitera, F. Manganelli, R. Iodice, G. Caporaso, A. Stancanelli, K. Marinou, B. 
Lanzillo, L. Santoro, and G. Mora. 2017. Non-motor involvement in amyotrophic lateral sclerosis: 
new insight from nerve and vessel analysis in skin biopsy. Neuropathol. Appl. Neurobiol. 43: 119-
132. 
Phukan, J., N. P. Pender, and O. Hardiman. 2007. Cognitive impairment in amyotrophic 
lateral sclerosis. Lancet Neurol. 6: 994-1003. 
Pugdahl, K., A. Fuglsang-Frederiksen, M. de Carvalho, B. Johnsen, P. R. Fawcett, A. Labarre-
Vila, R. Liguori, W. A. Nix, and I. S. Schofield. 2007. Generalised sensory system abnormalities in 
amyotrophic lateral sclerosis: a European multicentre study. J. Neurol. Neurosurg. Psychiatry 78: 
746-749. 
Radtke, R. A., A. Erwin, and C. W. Erwin. 1986. Abnormal sensory evoked potentials in 
amyotrophic lateral sclerosis. Neurology 36: 796-801. 
Ren, Y., W. Liu, Y. Li, B. Sun, Y. Li, F. Yang, H. Wang, M. Li, F. Cui, and X. Huang. 2018. 
Cutaneous somatic and autonomic nerve TDP-43 deposition in amyotrophic lateral sclerosis. J. 
Neurol. 265: 1753-1763. 
Riancho, J., P. Bosque-Varela, S. Perez-Pereda, M. Povedano, A. L. de Munain, and A. 
Santurtun. 2018. The increasing importance of environmental conditions in amyotrophic lateral 
sclerosis. Int. J. Biometeorol. 62: 1361-1374. 
Riancho, J., I. Gonzalo, M. Ruiz-Soto, and J. Berciano. 2019. Why do motor neurons 
degenerate? Actualization in the pathogenesis of amyotrophic lateral sclerosis. Neurologia 34: 27-
37. 
Riancho, J., P. Lozano-Cuesta, A. Santurtun, P. Sanchez-Juan, J. M. Lopez-Vega, J. Berciano, 
and J. M. Polo. 2016. Amyotrophic Lateral Sclerosis in Northern Spain 40 Years Later: What Has 
Changed? Neurodegener. Dis. 16: 337-341. 
Riancho J, Castanedo-Vázquez D, Gil-Bea F, Tapia O, Arozamena J, Durán-Vían C, Sedano MJ, 
Berciano MT, Lopez de Munain A, Lafarga M. 2020. ALS-derived fibroblasts exhibit reduced 
proliferation rate, cytoplasmic TDP-43 aggregation and a higher susceptibility to DNA damage. J 
Neurol; 267: 1291-1299. 
 
Ringholz, G. M., S. H. Appel, M. Bradshaw, N. A. Cooke, D. M. Mosnik, and P. E. Schulz. 2005. 
Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology 65: 586-590. 
Rubio, M. A., M. Herrando-Grabulosa, J. J. Vilches, and X. Navarro. 2016. Involvement of 
sensory innervation in the skin of SOD1(G93A) ALS mice. J. Peripher. Nerv. Syst. 21: 88-95. 
 
 
This article is protected by copyright. All rights reserved. 
Sangari S , Iglesias C , El Mendili MM, Benali H,  Pradat PF, Marchand-Pauvert V. 2016. 
Impairment of Sensory-Motor Integration at Spinal Level in Amyotrophic Lateral Sclerosis. Clin 
Neurophysiol; 127: 1968-77 
 
Sangari S , Giron A , Marrelec G , Pradat PF , Marchand-Pauvert V. 2018. Abnormal Cortical 
Brain Integration of Somatosensory Afferents in ALS. Clin Neurophysiol; 129: 874-884 
 
Sassone, J., M. Taiana, R. Lombardi, C. Porretta-Serapiglia, M. Freschi, S. Bonanno, S. 
Marcuzzo, F. Caravello, C. Bendotti, and G. Lauria. 2016. ALS mouse model SOD1G93A displays early 
pathology of sensory small fibers associated to accumulation of a neurotoxic splice variant of 
peripherin. Hum. Mol. Genet. 25: 1588-1599. 
Schafer, M. K., S. Bellouze, A. Jacquier, S. Schaller, L. Richard, S. Mathis, J. M. Vallat, and G. 
Haase. 2017. Sensory neuropathy in progressive motor neuronopathy (pmn) mice is associated with 
defects in microtubule polymerization and axonal transport. Brain Pathol. 27: 459-471. 
Seki, S., T. Yamamoto, K. Quinn, I. Spigelman, A. Pantazis, R. Olcese, M. Wiedau-Pazos, S. H. 
Chandler, and S. Venugopal. 2019. Circuit-Specific Early Impairment of Proprioceptive Sensory 
Neurons in the SOD1(G93A) Mouse Model for ALS. J. Neurosci. 39: 8798-8815. 
Shimizu, T., K. Bokuda, H. Kimura, T. Kamiyama, Y. Nakayama, A. Kawata, E. Isozaki, and Y. 
Ugawa. 2018. Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral 
sclerosis. Neurology 90: e1578-e1587. 
Shimizu, T., A. Kawata, S. Kato, M. Hayashi, K. Takamoto, H. Hayashi, S. Hirai, S. Yamaguchi, 
T. Komori, and M. Oda. 2000. Autonomic failure in ALS with a novel SOD1 gene mutation. Neurology 
54: 1534-1537. 
Shimizu, T., Y. Nakayama, A. Funai, R. Morishima, K. Hayashi, K. Bokuda, Y. Nakata, and E. 
Isozaki. 2020. Progressive deterioration of sensory cortex excitability in advanced amyotrophic 
lateral sclerosis with invasive ventilation. Amyotroph. Lateral. Scler. Frontotemporal. Degener. 21: 
147-149. 
Simone, I. L., R. Tortelli, V. Samarelli, E. D'Errico, M. Sardaro, O. Difruscolo, R. Calabrese, V. 
Francesco, V, P. Livrea, and M. de Tommaso. 2010. Laser evoked potentials in amyotrophic lateral 
sclerosis. J. Neurol. Sci. 288: 106-111. 
Taiana, M., J. Sassone, and G. Lauria. 2016. Mutant SOD1 accumulation in sensory neurons 
does not associate with endoplasmic reticulum stress features: Implications for differential 
vulnerability of sensory and motor neurons to SOD1 toxicity. Neurosci. Lett. 627: 107-114. 
Tao QQ , Wei Q , Wu ZY. 2018. Sensory Nerve Disturbance in Amyotrophic Lateral Sclerosis. 
2018; 203: 242-245 
Theys, P. A., E. Peeters, and W. Robberecht. 1999. Evolution of motor and sensory deficits in 
amyotrophic lateral sclerosis estimated by neurophysiological techniques. J. Neurol. 246: 438-442. 
Truini, A., A. Biasiotta, E. Onesti, G. Di Stefano, M. Ceccanti, S. La Cesa, A. Pepe, C. Giordano, 
G. Cruccu, and M. Inghilleri. 2015. Small-fibre neuropathy related to bulbar and spinal-onset in 
patients with ALS. J. Neurol. 262: 1014-1018. 
 
 
This article is protected by copyright. All rights reserved. 
Van der Graaff MM , de Jong JMBV, Baas F, de Visser M. 2009 Upper Motor Neuron and 
Extra-Motor Neuron Involvement in Amyotrophic Lateral Sclerosis: A Clinical and Brain Imaging 
Review. Neuromuscular Disord; 19: 53-58 
van Es, M. A., O. Hardiman, A. Chio, A. Al Chalabi, R. J. Pasterkamp, J. H. Veldink, and L. H. 
van den Berg. 2017. Amyotrophic lateral sclerosis. Lancet 390: 2084-2098 
Vaughan, S. K., Z. Kemp, T. Hatzipetros, F. Vieira, and G. Valdez. 2015. Degeneration of 
proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis-causing 
mutations. J. Comp Neurol. 523: 2477-2494. 
Vaughan, S. K., N. M. Sutherland, S. Zhang, T. Hatzipetros, F. Vieira, and G. Valdez. 2018. The 
ALS-inducing factors, TDP43(A315T) and SOD1(G93A), directly affect and sensitize sensory neurons 
to stress. Sci. Rep. 8: 16582. 
Wallace VC, Ellis CM, Burman R, Knights C, Shaw CE, Al-Chalabi A. 2014.  The evaluation of 
pain in amyotrophic lateral sclerosis: a case controlled observational study. Amyotroph Lateral Scler 
Frontotemporal Degener; 15: 520–27. 
 
Zhou, F., R. Xu, E. Dowd, Y. Zang, H. Gong, and Z. Wang. 2014. Alterations in regional 
functional coherence within the sensory-motor network in amyotrophic lateral sclerosis. Neurosci. 
Lett. 558: 192-196. 
Zufiria, M., F. J. Gil-Bea, R. Fernandez-Torron, J. J. Poza, J. L. Munoz-Blanco, R. Rojas-Garcia, 
J. Riancho, and A. L. de Munain. 2016. ALS: A bucket of genes, environment, metabolism and 








This article is protected by copyright. All rights reserved. 
 
 
FIGURE 1. Evidences of sensory involvement in ALS from human studies. 
Sensory involvement in ALS patients include the peripheral nervous system, the spinal cord sensory 
ascending tracts, as well as the somatosensory cortex. This figure illustrates the main pathological 
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FIGURE 2. Preclinical evidences of sensory involvement in ALS. 
A spinal cord segment is represented. Dorsal root ganglion sensory neurons (DRGSN) may be a 
potential target of the disease. Similar pathogenic mechanisms to that observed in spinal cord 
anterior horn motor neurons (MNs) have been reported in DRGSN. These include mitochondrial 
dysfunction (1), cytoskeletal abnormalities (2), SOD1 aggregation (3) as well as pathological 
hyperexcitability (4). In addition, the sensory-motor networks at spinal cord, in which a direct 
interaction between DRGSNs and anterior horn MNs occurs, emerge as new potential pathogenic 
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TABLE 1. MAIN CLINICAL STUDIES SUPPORTING SENSORY INVOLVEMENT IN 
ALS 
 
Author (year) Number of 
patients 
Main findings 
Peripheral nervous system 
Heads et al 1991 - Early axonal atrophy, increased remyelination and predominance of smaller fiber 
diameters. 
Gregory et al 1993 19 ALS Axonal sensory nerve neuropathy. 
Hammad et al 2007  
 
103 ALS  Sensory symptoms in 32% of patients. 
Abnormalities in sural sensory nerve conduction in 27% of patients 
Histological abnormalities (large-calibre myelinated fibers loss, axonal loss and axonal 
regeneration) in 91% of patients. 
Isaacs et al 2007 5 ALS  Sensory neuropathy. 
Axonal degeneration in sural biopsy. 
Pugdahl et al 2007  88sALS Sensory neuropathy in 22.7% of patients. 
Luigetti et al 2012  17 ALS Axonal loss in up to a 2/3 of patients. 
Truini et al 2015  24 ALS  (11 
bulbar/13 
spinal) 
Abnormal thermal-pain thresholds and reduced intraepidermal nerve fibre density in 
spinal onset forms. 
Isak et al 2015 18 ALS/31 
control 
Distal sensory nerve conduction tests evaluating antidromic dorsal sural nerve exhibit a 
higher sensitivity. 
Dalla Bella et al 2016 
 
57 ALS Intraepidermal nerve fibers reduction. 
No correlation between intraepidermal nerve fibers and disease onset/course nor 
disease severity. 
Isak et al 2017 32 ALS/32 
contol 
No alteration in nerve conduction studies. 
Histological analysis with abnormal axonal swelling and fibers negative for GAP43 in 
ALS. 




Intraepidermal nerve fiber density reduction, loss of Meissner´s corpuscles and loss 
small vascular vessels in ALS. 
 
 
Ren et al 2018  18 ALS/ 18 
controls 
Reduction of the intraepidermal nerve fiber density and loss of Meissner´s corpuscles. 
TDP43 aggregates in nerve fibers. 




No significant differences in sensory nerve conduction studies. 
Liu J et al 2019 150 ALS  Sensory nerve conduction alterations in up to 15% of patients. 
Ascending spinal tracts 
Cosi et al 1984 45 ALS Pathological slowing along central sensory pathways. 
Altered amplitude of potentials in some ALS patients. 
Radtke et al 1986  17 ALS Altered SEPs in 56% of ALS patients. 
Theys et al 1999  50 ALS SEP abnormalities in up to 60% of ALS patients. 
No progression of SEPs abnormalities over 6 months. 




Altered LEPs in ALS patients 





LEP more sensitive to assess sensory disturbances in comparison to SEP (72 and 56 % 
respectively). 




DTI and MT MRI sequences appeared altered in anterolateral and dorsal segments of 
spinal cord of ALS patients.  
Iglesias et al 2015 21 ALS/21 
control 
Combination of both DTI sequences and SEP identified subclinical sensory defects in 
up to 85 percent of ALS patients at early stages of the disease. 
Somatosensory cortex 
Hamada et al 2007 26 ALS/15 
control 
Cortical SEPs amplitude are associated to motor disturbances.  
Early cortical response appears enlarged in ALS patients at a moderate stage and 
markedly attenuated in patients with more advanced forms. 
Mochizuki et al 2011 - Concomitant neuronal loss at primary motor cortex and somatosensory cortex in ALS 
patients. 




Sensory-motor network impairment is associated to more severe forms of the disease 




Larger somatosensory cortical amplitudes in SEPs are an independent factor for poor 
prognosis in ALS patients. 
Nardone et al 2020 
 
- Marked disinhibition of somatosensory cortex in ALS patients from year 2 of disease 
evolution onwards 
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TABLE 2. MAIN PRECLINICAL STUDIES SUPPORTING SENSORY INVOLVEMENT 
IN ALS 
 
Author Animal model Main findings 
 
Guo et al. 2009 
 
hSOD1G93A mice 
Wallerian-like degeneration in axons of both dorsal root and 
dorsal funiculus. 
Mitochondrial abnormalities in dorsal root ganglia sensory 
neurons. 
Vaughan et al. 2015 
hSOD1 (G93A) mice 
TDP43 (A315T) mice 
Early disturbances in Ia and II proprioceptive nerve endings in 
muscle spindles before initiation of the motor symptomatic 
phase 
Rubio et al. 2016 hSOD1-G93A mice 
Marked reduction of intraepidermal nerve fibers, Meissner’s 
corpuscles, and subepidermal nerve density at early stages. 
 
Sassone et al. 2016 
 
hSOD1-G93A mice 
Small fiber pathology with intraepidermal nerve fiber loss and 
axonal degeneration, possibly induced by peripherin 56 
accumulation. 
Taiana et al. 2016 hSOD1-G93A mice 
Misfolded SOD1 accumulation in dorsal ganglion sensory 
neurons. 
No evidence of ER stress neither UPR activation. 
 
Schafer et al. 2017 
 
PMN mice 
Axonal sensory nerve pathology. 
Disorders in microtubule-based transport in dorsal root ganglion 
neurons. 
 
Schafer et al. 2017 
 
PMN mice 
Axonal sensory nerve pathology. 
Disorders in microtubule-based transport in dorsal root ganglion 
neurons. 
Vaughan et al. 2018 
SOD1(G93A) and TDP43 (A315T) 
sensory neurons 
Slower rates of neurite growth and fewer neuritic elaboration in 
mutated neurons. 
Differential response to stress between SOD1 and TDP43 
sensory neurons. 
 
Held et al. 2019 
 
Sod1-G85R Drosophila 
Defect in the sensory feedback as a potential initiating event for 
ALS motor dysfunction. 
Seki et al. 2019 hSOD1-G93A mice 
Early proprioceptive sensory neurons degeneration. 
Nav1.6 Na+ channel deficiency contributing to arrhythmic burst 
discharge. 
ER: endoplasmic reticulum; PMN: progressive motor neuronopathy; UPR: unfolded protein response 
 
 
